Geoffrey Gotto, MD, MPH, FRCSC

Clinical Professor, Department of Surgery, University of Calgary; Fellowship in Urologic Oncology, MSKCC; Masters in Public Health, Harvard

[Daniel Heng @DrDanielHeng]

Tremendous work Dr Taplin @drgotto @DanaFarberNews on this Plenary at #ASCO26. MFS is a meaningful endpoint and patient selection is key. Great discussion from @declangmurphy @gu_onc @OncoAlert

[Geoffrey Gotto, MD, MPH, FRCSC @drgotto]

@LauraBukavinaMD @MillanBraden @hjwang26 @UroOnc @UrolOncol @CleClinicUro Nice work Betty!

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

EMBARK: Overall survival with enzalutamide in biochemically recurrent #ProstateCancer Presented at #ESMO25

https://t.co/o6IM9YO5gi

Enzalutamide plus leuprolide significantly improves overall survival and delays disease progression compared with leuprolide alone in high-risk biochemically recurrent prostate cancer, supporting it as a standard-of-care option.

@SFreedlandMD
Neal Shore @CURCMB
@drgotto
@RannikkoAntti
@ArnauldVillers
@DrHWoo

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@nataliagandur
@bavilima

[UroToday.com @urotoday]

Perioperative enfortumab vedotin + pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible: the phase 3 KEYNOTE-905 study. Presented by Christof Vulsteke, MD, PhD. #ESMO25 written coverage by @chavarriagaj @UofT > https://t.co/a2hMJIAnSX @myESMO @UroDocAsh

[UroToday.com @urotoday]

Real-world experience with darolutamide in 799 patients with #nmCRPC: a prespecified interim analysis of the #DAROL prospective observational study. Presented by Murilo de Almeida Luz, MD. #ESMO25 written coverage by @zklaassen_md > https://t.co/JCHVAVUDGI @myESMO

[Open Medicine Insights @OpenMedInsights]

💫🌟Niraparib + Abiraterone + Prednisone in HRR-deficient mCSPC.🌟💫 https://t.co/hdFBl8jEgJ @AttardLab @neerajaiims @SandhuShahneen @EfstathiouEleni @drgotto @heatherhcheng @Dolmos77 @drenriquegrande @DRathkopf
@uclcancer @huntsmancancer @seattlecca @fredhutch @uwmedicine @PCF_Science @sloan_kettering
@OncoAlert
💥 First Phase III evidence of PARP inhibition in mCSPC!

🔹 Design: Double-blind, randomized (n=696), HRR+ (56% BRCA1/2)
🔹 Primary endpoint met:
 • rPFS HR 0.52 (BRCA) → NE vs 26 mo
 • rPFS HR 0.63 (ITT) → NE vs 29.5 mo
🔹 Time to symptomatic progression HR 0.50
🔹 OS (immature): HR 0.79, trend favoring niraparib
🔹 Toxicities: Anemia 29%, Hypertension 27%, manageable
🔹 HRR testing now essential at mCSPC diagnosis

🧠 Clinical impact:
Niraparib + Abiraterone delivers significant PFS improvement in BRCA1/2 mCSPC—marking the PARPi era’s entry into hormone-sensitive disease.

@myESMO @ASCO @UroToday @NatureMedicine @Uromigos
#ProstateCancer #mCSPC #HRR #PARPi #Niraparib #PrecisionOncology #GUOnc #OncoTwitter

[Neeraj Agarwal, MD, FASCO @neerajaiims]

🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 https://t.co/BYx1L9i7GC @PCFnews @OncoAlert @urotoday

[Geoffrey Gotto, MD, MPH, FRCSC @drgotto]

@DrDanielHeng @Nimira_A @albertacancer @UCalgaryMed @AHS_CancerCare Rockstar

[UroToday.com @urotoday]

Third interim analysis of the DARolutamide ObservationaL #DAROL study in patients with #nmCRPC. Presentation by @drgotto @UCalgary. #AUA24 written coverage by @RKSayyid @UofT > https://t.co/HUQuPOZ5of @AmerUrological

[Heidi Rayala @HeidiRayala]

"Remember that life's most valuable antiques are dear old friends."
@UrologyMSK @doreenchungMD @LonestarUroDoc @drgotto

[UroToday.com @urotoday]

Third interim analysis of the DARolutamide ObservationaL #DAROL study in patients with #nmCRPC. Presented by @drgotto @UCalgary. #AUA24 written coverage by @RKSayyid @UofT > https://t.co/PPTRmQdzH9 @AmerUrological

[Geoffrey Gotto, MD, MPH, FRCSC @drgotto]

Great meeting @pcvblack !

[Peter Black @pcvblack]

Full house for regional GU Onc meeting! #WCUOG @CanUrolAssoc

[Tom Powles @tompowles1]

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

[NEJM @NEJM]

In patients with high-risk biochemically recurrent prostate cancer, treatment with enzalutamide and leuprolide improved metastasis-free survival as compared with leuprolide alone. Read the full results of the EMBARK phase 3 trial): https://t.co/T8hSkTMLO8

[Geoffrey Gotto, MD, MPH, FRCSC @drgotto]

@FionaMattatall @GAbelseth @docstrongarm I feel like I deserve honourary team membership 😉

[Geoffrey Gotto, MD, MPH, FRCSC @drgotto]

@AssmusMark @amy_krambeck 👊

[ProstateCancerCentre @prostatealberta]

Thank you to @BioAroInc & @AnmolMD for generously donating genomic testing services FREE of charge to 100 eligible patients. This will revolutionize the treatment of metastatic prostate cancer patients!

[Geoffrey Gotto, MD, MPH, FRCSC @drgotto]

Excited to see these #EMBARK results presented at #AUA23 Thanks for your leadership @SFreedlandMD and @nealshore

[Stephen Freedland, MD @SFreedlandMD]

Proud to have co-led the #practicechanging #EMBARK trial with @nealshore showing improved #MFS and trends for better survival for #enzalutamide with or without #ADT. #AUA23 @pfizer @AstellasUS @CSCancerCenter @CedarsSinaiMed

[UroToday.com @urotoday]

Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive #ProstateCancer. Presentation by @drgotto @saiuCalgary. @ASCO #GU23 written coverage by @WallisCJD @UofT > https://t.co/bsD0P35kgG

[Geoffrey Gotto, MD, MPH, FRCSC @drgotto]

@VickersBiostats Amazing 😂